![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1620, 2008-01, pp. : 15-16
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Doxorubicin + docetaxel vs standard chemo in breast cancer
Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Doxorubicin liposomal + docetaxel: efficacy in metastatic breast cancer?
Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel regimen improves survival in early breast cancer
Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Gemcitabine/epirubicin/docetaxel effective in early breast cancer
Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel/carboplatin combo delivers in ovarian cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 631, 2011-01 ,pp. :